What is LLY's market cap?

$1.26T, based on the Nov 4 close of $1,417.99.

What is LLY's P/E ratio?

45.8× trailing-twelve-month earnings of $27.58B.

Does Eli Lilly & pay a dividend?

Yes. The latest regular dividend was $1.73 per share (ex-date Aug 14), an annualised yield of 0.49%.

How much of LLY is sold short?

7.0M shares, 0.8% of float, as of Oct 15, 2026.

What sector is LLY in?

Healthcare, in the Pharmaceuticals industry.

NYSE · LLYHealthcarePharmaceuticals

Eli Lilly & Co. (LLY)

$1,417.99+0.61%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1417.99▲ 56.36% in range

Nov 4, 2025Low $851.21 · High $1417.99Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Eli Lilly & closed at $1,417.99 on Nov 4, up 0.61% — matching its 52-week closing high. Volume of 3.6M shares was 1.37× its 20-day average (above normal).

Split-adjusted performance: +22.5% over one month, +43.7% over six months, +58.2% over one year.

In the quarter ended Sep 30, 2026, revenue was $24.40B, up 38.6% from a year earlier, with a net margin of 26.4%.

Short interest was 7.0M shares at the Oct 15 settlement, down 1.1% from the prior report (0.8% of float, 3.0 days to cover).

Market cap$1.26T890.7M shares

Revenue · quarter$24.40B+38.6% YoY

Diluted EPS$7.22+16.3% YoY

P/E · TTM45.8×P/S 14.6×

Net margin26.4%Gross 83.9%

Dividend yield0.49%$1.73 last paid

52-week range851.21 – 1417.990.0% from high

Volume3.6M1.37× 20-day avg

Volatility · 60d29.8%Annualised

Short % of float0.8%3.0 days to cover

Net cash-$44.62BCash $4.88B

Next earnings—Not scheduled

Split-adjusted performance

1W +10.1%1M +22.5%3M +19.0%6M +43.7%YTD +31.9%1Y +58.2%3Y +150.7%5Y +466.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum91

Revenue growth75

Net margin88

Value (low P/E)22

Size100

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short7.0M−1.1% vs prior

Days to cover3.0Settled Oct 15

% of float0.8%

Short vol. 10d36.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
LLYEli Lilly &	$1,417.99	+0.61%	+43.7%	+38.6%	26.4%	45.8	$1.26T
JNJJohnson & Johnson	$276.32	+3.81%	+23.0%	+5.9%	0.8%	41.3	$665.19B	Compare
ABBVABBVIE	$294.83	+3.09%	+43.8%	+10.3%	24.2%	50.4	$521.00B	Compare
MRKMerck & Co.	$150.36	+3.93%	+32.4%	+5.1%	−8.0%	116.9	$370.96B	Compare
ABTAbbott Laboratories	$115.51	+5.58%	+33.8%	+13.0%	7.4%	36.8	$199.88B	Compare
PFEPfizer	$30.79	+2.63%	+16.1%	+2.6%	−1.6%	40.5	$175.49B	Compare
VRTXVertex Pharmaceuticals	$549.04	+3.44%	+28.4%	+11.8%	19.0%	35.0	$139.16B	Compare
BMYBristol-Myers Squibb	$64.19	+4.02%	+13.4%	+5.7%	25.6%	14.1	$131.21B	Compare
REGNRegeneron Pharmaceuticals	$930.67	−4.39%	+29.1%	+36.3%	38.1%	20.0	$96.28B	Compare

News about Eli Lilly &

All news →

National Advertising Division Recommends Good Life Discontinue Health Benefit and Personalization Claims for Compounded Tirzepatide+ ProductsGlobeNewswire Inc. · 14h ago▲ Positive Top Analyst Reports for Eli Lilly, Cisco & KLAZacks Investment Research · 1d ago▲ Positive Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research · 1d agoNeutral LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?Zacks Investment Research · 1d ago▲ Positive After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?The Motley Fool · 4d ago▲ Positive

Quick answers

What does Eli Lilly & do?: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
What is LLY's market cap?: $1.26T, based on the Nov 4 close of $1,417.99.
What is LLY's P/E ratio?: 45.8× trailing-twelve-month earnings of $27.58B.
Does Eli Lilly & pay a dividend?: Yes. The latest regular dividend was $1.73 per share (ex-date Aug 14), an annualised yield of 0.49%.
How much of LLY is sold short?: 7.0M shares, 0.8% of float, as of Oct 15, 2026.
What sector is LLY in?: Healthcare, in the Pharmaceuticals industry.

About Eli Lilly &

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

HQ: Indianapolis, IN50,000 employeesListed Jul 9, 1970lilly.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology